PH12022551368A1 - Dendrimer compositions and methods for drug delivery - Google Patents
Dendrimer compositions and methods for drug deliveryInfo
- Publication number
- PH12022551368A1 PH12022551368A1 PH1/2022/551368A PH12022551368A PH12022551368A1 PH 12022551368 A1 PH12022551368 A1 PH 12022551368A1 PH 12022551368 A PH12022551368 A PH 12022551368A PH 12022551368 A1 PH12022551368 A1 PH 12022551368A1
- Authority
- PH
- Philippines
- Prior art keywords
- inhibitors
- methods
- dendrimers
- cancer
- compositions
- Prior art date
Links
- 239000000412 dendrimer Substances 0.000 title abstract 6
- 229920000736 dendritic polymer Polymers 0.000 title abstract 6
- 239000000203 mixture Substances 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 238000012377 drug delivery Methods 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 201000011510 cancer Diseases 0.000 abstract 3
- 239000003112 inhibitor Substances 0.000 abstract 3
- 208000023275 Autoimmune disease Diseases 0.000 abstract 2
- 239000013543 active substance Substances 0.000 abstract 2
- 239000005557 antagonist Substances 0.000 abstract 2
- 229920000962 poly(amidoamine) Polymers 0.000 abstract 2
- 208000020084 Bone disease Diseases 0.000 abstract 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 abstract 1
- 239000005977 Ethylene Substances 0.000 abstract 1
- 102000009127 Glutaminase Human genes 0.000 abstract 1
- 108010073324 Glutaminase Proteins 0.000 abstract 1
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 abstract 1
- 102000002791 Interleukin-8B Receptors Human genes 0.000 abstract 1
- 108010018951 Interleukin-8B Receptors Proteins 0.000 abstract 1
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 abstract 1
- 239000012661 PARP inhibitor Substances 0.000 abstract 1
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 abstract 1
- 229940044665 STING agonist Drugs 0.000 abstract 1
- 108091008605 VEGF receptors Proteins 0.000 abstract 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 abstract 1
- 208000018339 bone inflammation disease Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000002519 immonomodulatory effect Effects 0.000 abstract 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 abstract 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/595—Polyamides, e.g. nylon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962943705P | 2019-12-04 | 2019-12-04 | |
| US202063108186P | 2020-10-30 | 2020-10-30 | |
| PCT/US2020/063332 WO2021113651A2 (en) | 2019-12-04 | 2020-12-04 | Dendrimer compositions and methods for drug delivery |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12022551368A1 true PH12022551368A1 (en) | 2023-05-08 |
Family
ID=74104190
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH1/2022/551368A PH12022551368A1 (en) | 2019-12-04 | 2020-12-04 | Dendrimer compositions and methods for drug delivery |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20230226199A1 (enExample) |
| EP (1) | EP4069307A2 (enExample) |
| JP (1) | JP2023504286A (enExample) |
| CN (1) | CN115103689A (enExample) |
| AU (1) | AU2020397063A1 (enExample) |
| CA (1) | CA3163886A1 (enExample) |
| IL (1) | IL293604A (enExample) |
| PH (1) | PH12022551368A1 (enExample) |
| WO (1) | WO2021113651A2 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021113662A2 (en) | 2019-12-04 | 2021-06-10 | Ashvattha Therapeutics, Inc. | Dendrimer compositions and methods for drug delivery to the eye |
| JP2023522984A (ja) | 2020-04-24 | 2023-06-01 | アシュバッタ セラピューティクス， インコーポレイテッド | 重症急性呼吸促迫症候群の処置のためのデンドリマー組成物および方法 |
| PH12023550133A1 (en) * | 2020-07-17 | 2024-06-24 | Ashvattha Therapeutics Inc | Dendrimer compositions and methods for drug delivery to injured kidney |
| JP2023549081A (ja) * | 2020-10-30 | 2023-11-22 | アシュバッタ セラピューティクス， インコーポレイテッド | Ｐｅｔイメージングおよび放射線療法のための放射標識エーテルデンドリマーコンジュゲート |
| WO2022192135A1 (en) * | 2021-03-08 | 2022-09-15 | Transdermal Biotechnology, Inc. | Dendrimer-n-actyl-l-cysteine conjugates for treatment or prevention of aging skin or other indications |
| TW202313118A (zh) * | 2021-06-10 | 2023-04-01 | 美商阿什瓦塔治療股份有限公司 | 樹枝狀體結合物及其使用方法 |
| EP4490158A4 (en) * | 2022-03-10 | 2026-01-07 | Curators Of The University Of Missouri The | NEW PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITOR, COMPOSITIONS CONTAINING IT, METHODS OF MANUFACTURING IT AND METHODS OF TREATING A DISEASE |
| WO2023183367A1 (en) * | 2022-03-22 | 2023-09-28 | Board Of Regents Of The University Of Nebraska | Metformin nanoformulations and methods of use thereof |
| EP4496568A1 (en) * | 2022-03-22 | 2025-01-29 | Board of Regents of the University of Nebraska | Metformin nanoformulations and methods of use thereof |
| CN114796492B (zh) * | 2022-05-12 | 2023-01-13 | 大连理工大学 | 一种超声驱动纳米声敏疫苗及其制备和应用 |
| CN116196292B (zh) * | 2023-02-16 | 2024-08-16 | 东华大学 | 一种靶向肽修饰的聚酰胺-胺树状大分子复合纳米材料及其制备方法 |
| WO2025183982A1 (en) * | 2024-02-28 | 2025-09-04 | Washington State University | Psma-targeted dendrimer nanoplatform for cancer detection and therapy |
| WO2025226820A1 (en) * | 2024-04-23 | 2025-10-30 | Ashvattha Therapeutics, Inc. | Csf1r inhibitor dendrimer conjugates and uses thereof |
| CN118108799B (zh) * | 2024-04-29 | 2024-07-12 | 内蒙古工业大学 | 基于DMXAA的含Se多肽药物及其制备方法和应用 |
| WO2025259214A1 (en) | 2024-06-14 | 2025-12-18 | EGE Kimya San. ve Tic. A.S. | Use of dendrimer compounds as anti-skinning agents |
| WO2025259215A1 (en) | 2024-06-14 | 2025-12-18 | EGE Kimya San. ve Tic. A.S. | Use of dendrimer compounds as complexing ligands for metal activity enhancement |
| CN118846078A (zh) * | 2024-07-02 | 2024-10-29 | 中国人民解放军空军军医大学 | Ndrg2基因联合分子靶向抑制剂在制备肾细胞癌治疗药物中的应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3856807A (en) | 1972-03-13 | 1974-12-24 | Upjohn Co | L-({60 s,5s)-{60 -amino-3-chloro-2-isoxazoline-5-acetic acid |
| US3878047A (en) | 1973-02-02 | 1975-04-15 | Upjohn Co | Process for production of AT-125 |
| US5087639A (en) | 1988-11-02 | 1992-02-11 | The Upjohn Company | Preventing CNS toxicity of acivicin when used with four large neutral amino acids |
| CA2786794C (en) * | 2004-03-23 | 2017-09-12 | Complex Biosystems Gmbh | Aromatic polymeric cascade prodrug linker reagent |
| EP2214646B1 (en) | 2007-10-05 | 2021-06-23 | Wayne State University | Dendrimers for sustained release of compounds |
| CA2767163A1 (en) | 2009-06-15 | 2010-12-23 | Wayne State University | Dendrimer based nanodevices for therapeutic and imaging purposes |
| WO2011123591A1 (en) | 2010-03-31 | 2011-10-06 | Wayne State University | Injectable dendrimer hydrogel nanoparticles |
| US9198973B2 (en) * | 2013-06-17 | 2015-12-01 | Fundacion Fraunhofer Chile Research | PAMAM, spacer molecule and cafestol polymers |
| EP3137116B1 (en) * | 2014-04-30 | 2020-12-16 | The Johns Hopkins University | Dendrimer compositions and their use in treatment of diseases of the eye |
| ES2910550T3 (es) * | 2014-05-21 | 2022-05-12 | Icd Therapeutics Gmbh | Conjugados terapéuticos con dendrímeros sulfatados para selección de objetivos intracelulares |
| EP3180031A1 (en) * | 2014-08-13 | 2017-06-21 | The Johns Hopkins University | Selective dendrimer delivery to brain tumors |
| WO2016025745A1 (en) | 2014-08-13 | 2016-02-18 | The Johns Hopkins University | Dendrimer compositions and use in treatment of neurological and cns disorders |
| MX2017007873A (es) * | 2014-12-15 | 2017-11-06 | Univ Johns Hopkins | Formulaciones de sunitinib y metodos para uso de las mismas en el tratamiento de trastornos oculares. |
| KR101918346B1 (ko) * | 2015-05-06 | 2018-11-13 | 경북대학교 산학협력단 | 난용성 활성물질의 수용성 덴드리머 복합체 |
| CN108289872B (zh) * | 2015-10-29 | 2021-04-02 | 约翰霍普金斯大学 | 树枝状聚合物组合物和其在坏死性小肠结肠炎和其它胃肠道病症治疗中的用途 |
| US20190142953A1 (en) * | 2016-05-10 | 2019-05-16 | Massachusetts Institute Of Technology | Dendrimer-Drug Conjugates, Hydrogel Compositions, and Methods |
| TWI773730B (zh) * | 2017-02-22 | 2022-08-11 | 瑞典商阿斯特捷利康公司 | 治療性樹枝狀聚合物 |
| US12290571B2 (en) * | 2017-10-05 | 2025-05-06 | Sony Group Corporation | Programmable dendritic drugs |
| WO2019094952A1 (en) * | 2017-11-10 | 2019-05-16 | The Johns Hopkins University | Dendrimer delivery system and methods of use thereof |
| WO2020132196A1 (en) * | 2018-12-21 | 2020-06-25 | Tiba Biotech Llc | Nanoparticle compositions for efficient nucleic acid delivery and methods of making and using the same |
| WO2021113662A2 (en) * | 2019-12-04 | 2021-06-10 | Ashvattha Therapeutics, Inc. | Dendrimer compositions and methods for drug delivery to the eye |
-
2020
- 2020-12-04 CA CA3163886A patent/CA3163886A1/en active Pending
- 2020-12-04 US US17/782,592 patent/US20230226199A1/en active Pending
- 2020-12-04 EP EP20830427.9A patent/EP4069307A2/en active Pending
- 2020-12-04 US US17/112,541 patent/US20210170040A1/en not_active Abandoned
- 2020-12-04 IL IL293604A patent/IL293604A/en unknown
- 2020-12-04 PH PH1/2022/551368A patent/PH12022551368A1/en unknown
- 2020-12-04 WO PCT/US2020/063332 patent/WO2021113651A2/en not_active Ceased
- 2020-12-04 JP JP2022534289A patent/JP2023504286A/ja active Pending
- 2020-12-04 AU AU2020397063A patent/AU2020397063A1/en active Pending
- 2020-12-04 CN CN202080095453.0A patent/CN115103689A/zh active Pending
-
2022
- 2022-10-07 US US17/962,297 patent/US20230372499A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20210170040A1 (en) | 2021-06-10 |
| US20230226199A1 (en) | 2023-07-20 |
| IL293604A (en) | 2022-08-01 |
| CN115103689A (zh) | 2022-09-23 |
| CA3163886A1 (en) | 2021-06-10 |
| JP2023504286A (ja) | 2023-02-02 |
| AU2020397063A1 (en) | 2022-07-07 |
| US20230372499A1 (en) | 2023-11-23 |
| WO2021113651A3 (en) | 2021-08-26 |
| EP4069307A2 (en) | 2022-10-12 |
| WO2021113651A2 (en) | 2021-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2021113651A3 (en) | Dendrimer compositions and methods for drug delivery | |
| Curto‐Reyes et al. | Spinal and peripheral analgesic effects of the CB2 cannabinoid receptor agonist AM1241 in two models of bone cancer‐induced pain | |
| Schmidt | The neurobiology of cancer pain | |
| MX390535B (es) | Compuestos de amino-triazolopiridina y su uso en el trataniento del cancer. | |
| PH12022551369A1 (en) | Dendrimer compositions and methods for drug delivery to the eye | |
| MX2020013570A (es) | Compuestos de purinona y su uso en el tratamiento del cancer. | |
| UA99608C2 (en) | PDGFRb-SPECIFIC INHIBITORS | |
| WO2004098589A8 (en) | 4- bromo - 5 - (2- chloro - benzoylamino) - 1h - pyrazole - 3 - carboxylic acid amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases | |
| DK1187918T4 (da) | TEK-antagonister | |
| IL219857A0 (en) | Mitotic kinesin inhibitors, pharmaceutical compositions comprising them, uses thereof in the manufacture of a medicament for the treatment of disease or disorder in a human or animal that can be treated by inhibiting mitosis | |
| EP3150635A3 (en) | Methods for treating disseminated intravascular coagulation by inhibiting masp-2 dependent complement activation | |
| ATE551060T1 (de) | Zusammensetzungen und verfahren zur behandlung von neovaskulären erkrankungen | |
| CR7432A (es) | Amidas sustituidas activas del receptor de canabinoide-1 | |
| EP2381775A4 (en) | INHIBITORS OF NECROPTOSIS OF SMALL MOLECULAR SIZE | |
| NO20026255D0 (no) | Polymere micelle sammensetninger | |
| BR0116575A (pt) | Terapia combinada que usa inibidores de tirosina cinase receptora e inibidores de angiogênese | |
| CY1106600T1 (el) | Ανθεκτικη, στη φθορα συνεξωθημενη μορφη δοσολογιας που περιεχει εναν ενεργο παραγοντα και εναν ανταγωνιστικο παραγοντα και διαδικασια παρασκευης αυτης | |
| MXPA04001187A (es) | Receptores de interleucina-1 en el tratamiento de enfermedades. | |
| MX336881B (es) | Compuestos heterociclicos triciclicos. | |
| MXPA05011524A (es) | Acidos carboxilicos sustituidos. | |
| MX2023010711A (es) | Fenalquilaminas y métodos de preparación y uso de las mismas. | |
| MX2019010898A (es) | Compuestos de tipo imidazo[4,5-c]quinolin-2-ona deuterados y su uso en el tratamiento del cancer. | |
| WO2006034048A8 (en) | Therapeutic agents targeting the ncca-atp channel and methods of use thereof | |
| CY1115908T1 (el) | Υγρη συνταγοποιηση προϊοντος συζευξης g-csf | |
| PH12023550133A1 (en) | Dendrimer compositions and methods for drug delivery to injured kidney |